Improving Lives Through Imaging & Targeted Therapy

Learn More
What do we do?

Theranostics

Imaging / Therapy

Cell Theranostics, Ltd.

Cell Theranostics is a late-stage Phase 3 biotech company specializing in the field of theranostic nuclear medicine through chelation technologies focused in cancer, cardiovascular, neuroendocrine, diabetes and ischemia-based diseases. 

The company acquired five platform technologies that are in late-stage development from The University of Texas M.D. Anderson Cancer Center.  

Our Lead Product – Oncardia 


Cell Theranostics lead product in clinical development is ethylenedicysteine-glucosamine which the Company registered under the trademark “Oncardia”. With applications in cancer and cardiovascular disease, Oncardia can be radiolabeled or complexed with cold metals to create a range of nuclear imaging and therapeutic product compounds.  Oncardia is able to target the diseased cell where it is fully phosphorylated and enters the cell nucleus. This enables Oncardia to serve as a uniquely effective diagnostic and therapeutic platform for drug development and clinical applications.  Oncardia can be conveniently labeled with technetium-99m (99mTc) for imaging with SPECT and SPECT/CT camera systems or gallium-68 (68Ga) for imaging with PET and PET/CT camera systems. For therapy, Oncardia can be complexed with a cold metal for intra-nuclear metallic therapy such as platinum or rhenium-187 (187Re), or it can be labeled with radionuclides like lutetium-177 (177Lu) or rhenium-188 (188Re) for intra-nuclear radiotherapy.

Read More
5

Platform Technologies Acquired from the University of Texas M.D. Anderson Cancer Center

4

Platform Technologies Are Based on Chelation Chemistry

14

Molecular Imaging Agents

4

Targeted Intra-Nuclear Therapeutics

148

Patents Granted Worldwide

9

Patents Pending

Have questions?

Frequently Asked

Read All FAQs

Theranostics

Theranostic medicine is a major step forward in making personalized medicine a reality. It is the combination of target specific diagnostic imaging and compatible target specific therapy at the molecular level.

Explore

Cancer Imaging

Before the development of FDG-PET/CT, medical oncologists were limited to standard X-ray, CT, MRI, Ultrasound and some utilization of nuclear imaging. FDG-PET/CT ushered in a new approach to cancer diagnostics by creating 3-D images at the molecular level.  Oncardia has the potential to shift the paradigm to a more accurate, accessible, and cost-effective way to diagnose and stage cancer without the drawbacks of FDG used in PET-CT imaging.

Explore

Cardiac Imaging

Nuclear cardiology needs an agent that eliminates the drawbacks associated with perfusion imaging to diagnose the presence and extent of myocardial ischemia. At Cell Theranostics we are making that a reality.

Explore

News & Publications

View All

MedAxiom Announces Industry Partnership With Cell>Point

MedAxiom Announces Industry Partnership With Cell>Point with Video Cell>Point, improving lives through imaging and targeted therapy. Partner News…

Read

Cell>Point plans to expedite research program on 99mTc-EC-Amifostine and 177Lu-EC- Amifostine as a potentially effective theranostic technology for COVID-19

CENTENNIAL, Colorado, March 24, 2020 – Cell>Point announced today its plans to move forward with its research program…

Read

Cell>Point Expanding Theranostic Clinical Research to Include Platinum and 177Lu Targeted Therapy to Compliment Oncardia Imaging Platform

CENTENNIAL, Colorado, January 21, 2020 – Cell>Point announced today, based on its sponsored chelator and therapeutic research conducted…

Read

Cell>Point announced today that it plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in patients suffering from coronary artery disease using the new one-vial Oncardia

CENTENNIAL, Colorado, May 17, 2019 – Cell>Point announced today that it plans to begin patient recruitment for its…

Read

Latest Findings

On Research

Learn More